hERG1 is also highly expressed in primary Gastric Cancer (GC): a study performed on 508 surgical samples showed a hERG1 immunoreactivity in 69% of cases, with a statistically significant negative prognostic impact in early-stage GC and in precancerous lesions (gastric metaplasias and dysplasias) [96]. The gene discussed is KCNH2; the disease is dysplasia.